Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Australian pharma warns TGA against removing fee incentives for orphan drugs

This article was originally published in SRA

Executive Summary

Australia's pharmaceutical industry association, Medicines Australia, has objected to proposals by the Therapeutic Goods Administration to eliminate fee waivers for the registration and evaluation of orphan drugs1. The association warns that if this incentive is removed, "local sponsors may not invest in bringing these products to market in Australia as this would not be commercially viable in many instances".

Advertisement
Advertisement
UsernamePublicRestriction

Register